Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838561 | 0.67 | CA12 (1.00) | CA9CA12KMT2ALMNAALDH1A1 | |
| Acesulfame SCHEMBL3551 | 0.66 | CA9 (1.00) | CA9CA12KMT2A | |
| Acesulfame SCHEMBL7594675 | 0.66 | CA9 (1.00) | CA9CA12KMT2A | |
| SCHEMBL3189685 | 0.64 | CA9 (0.38) | CA9CA12MEN1KMT2AALDH1A1 | |
| SCHEMBL3179809 | 0.64 | DRD2 (0.40) | CA9CA12MEN1POLBKMT2A | |
| Acesulfame SCHEMBL3126570 | 0.64 | CA9 (0.96) | CA9CA12KMT2A | |
| Potassium SCHEMBL38656592 | 0.64 | CA9 (0.55) | CA9CA12 | |
| Acesulfame SCHEMBL7568032 | 0.64 | CA9 (0.96) | CA9CA12KMT2A | |
| Acesulfame SCHEMBL38655123 | 0.64 | CA9 (0.96) | CA9CA12KMT2A | |
| Acesulfame SCHEMBL38656077 | 0.64 | CA9 (0.96) | CA9CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023119910-A1 | RADIATION-SENSITIVE COMPOSITION, RESIST PATTERN FORMATION METHOD, ACID GENERATOR, AND COMPOUND | JSR株式会社 | 2023-06-29 | — | — | WO | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-2859961-A2 | Methods and compositions for metal nanoparticle treated surfaces | Avent, Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-1991365-B1 | METHODS FOR FORMING SILVER-NANOPARTICLE TREATED SURFACES | KIMBERLY CLARK CO (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122321-A1 | Methods and Compositions for Metal Nanoparticle Treated Surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361553-B2 | Methods and compositions for metal nanoparticle treated surfaces | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20090318685-A1 | METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-7408059-B2 | 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide; cyclizing a beta-ketoamide-N-sulfonic acid with an acid anhydride | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070207335-A1 | Methods and compositions for metal nanoparticle treated surfaces | AVANOS MEDICAL SALES, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20050182255-A1 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | DAICEL CHEMICAL INDUSTRIES, LTD. | 2005-08-18 | — | — | US | disclosed |
| EP-1564211-A1 | Method for producing 3,4-Dihydro-1,2,3-Oxathiazin-4-one-2,2-Dioxide compound or salt thereof | Daicel Chemical Industries, Ltd. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182255-A1 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | CA2, HAO2, SRD5A2 | CA9 124/4885CA12 37/4885MEN1 3623/4885 |
| US-10251392-B2 | Antimicrobial devices and compositions | AAAS, AOC1, COL14A1 | CA9 1224/4885CA12 923/4885MEN1 4622/4885 |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | CA9 1224/4885CA12 923/4885MEN1 4622/4885 |
| US-20090318685-A1 | METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF | CA2, HAO2, KYAT1 | CA9 110/4885CA12 67/4885MEN1 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.